ARCHIVES

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

This article is from The Cancer Letter archive.

Vol. 25 No. 7 | July 26, 2002

Download PDF Visit The Full Archive

Related Articles

Efaproxyn Improved Survival Of Patients With Brain Mets

October 29, 2004

NCAB Committee Approves Concepts For Recompetition Of CIDAC, Two Other Contracts

July 1, 1983

In Brief: Cancer Control Funds For Clinical Trials Intended To Upgrade Quality of Care: Terry

January 16, 1981

NCI, SAIC To Support Contracts For Molecular Target Labs.

February 25, 2000

Zevalin Regimen Effective In Mantle Cell Lymphoma

January 30, 2004

Group Lobby To Add $200 Mil. To Cancer Budget

April 26, 1991